Low Intensity Linear Shockwave Therapy for Erectile Dysfunction
- Conditions
- Vasculogenic Erectile Dysfunction
- Interventions
- Device: Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction
- Registration Number
- NCT03843086
- Lead Sponsor
- University of Virginia
- Brief Summary
MoreNovaED is a Linear Shockwaves (LISW) device in which shockwaves are focused onto line segments for improved organ coverage. Shockwaves produced by MoreNovaED are aimed at the left and right corpora cavernosa and the crura. The study is aimed at determining the safety and effectiveness of this new type LISW in the relief of ED.
- Detailed Description
Morenova-Erectile dysfunction (ED) is a Linear Shockwaves (LISW) device which incorporates a unique shockwave transducer operable to deliver shockwaves to a treated region confined to a narrow rectangle. Shockwaves generation follows the electromagnetic principle. Low intensity shockwaves do not inflict pain and anesthesia or sedation is not required.
This current study is a prospective, pilot, randomized, uncontrolled clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic ED patients. The patients are randomized in a 1:1 ratio into active treatment groups.
Rationale:Linear Shockwaves has been known to bolster angiogenesis by increasing the levels of vascular endothelial growth factor.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Male
- Target Recruitment
- Not specified
- The patient has been correctly informed about the study
- The patient must have given his informed and signed consent
- The patient is a man between 40 and 80 years of age
- The patient has ED of Vasculogenic origin
- The patient is PDE5i responsive, meaning he is able to achieve and maintain an erection under the effect of the maximal dosage of PDE5i
- The patient has been in a stable heterosexual relationship for over 3 months prior to enrollment
- A minimum of 2 sexual attempts per month for at least one month prior to enrollment
- The patient is suffering from erectile dysfunction lasting for over 6 months and not more than 5 years
- IIEF-EF score between 17 and 25
- Testosterone level 300-1000 ng/dL within 1 month prior to enrollment
- A1C level ≤ 7% within 1 month prior to enrollment
- Patients have at least a natural tumescence during sexual stimulation (EHS score ≥ 1).
- The patient is participating in another study that may interfere with the results or conclusions of this study
- Within the past three months, the patient has participated in another study that may interfere with the results or conclusions of this study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection
- The patient is an adult under guardianship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- History of radical prostatectomy or extensive pelvic surgery
- Venous leak
- Past radiation therapy of the pelvic region within 12 months prior to enrollment
- Recovering from cancer within 12 months prior to enrollment
- Neurological disease which effects erectile function
- Psychiatric disease which effects erectile function
- Anatomical malformation of the penis, including Peyronie's disease
- Testosterone level <300 or >1000 ng/dL within 1 month prior to enrollment
- A1C level > 7% within 1 month prior to enrollment
- The patient is taking blood thinners and has an international normalized ratio >3.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 720 Low Intensity shockwave therapy Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction Five daily sessions within a week, Monday thru Friday, in which 720 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura) 600 Low Intensity shockwaves therapy Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction Three weekly sessions for 2 consecutive weeks, Monday-Wednesday-Friday, in which 600 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura) Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor in terms of type and dose of drug, for the remainder of study duration.
- Primary Outcome Measures
Name Time Method International Index of Erectile Function (IIEF-EF) Questionnaire 7 months The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials
- Secondary Outcome Measures
Name Time Method EHS (Erection Hardness Score) at follow-ups 7 months Scale rating hardness of erection from 0-4 with 4 being highest
SEP (Sexual Encounter Profile) 2 & 3 at follow-ups 7 months Sexual activity improvement leading to optimal penetration at follow-ups. 2 Yes or No questions
GAQ (Global Assessment Questions) at follow-ups 7 months 2 Yes or No questions assessing improvement with treatment